



Deep Brain Stimulation for Severe Mental Illness

Deep Brain Stimulation





- **Used by NHS for Parkinson's disease >25 years**
- **Modifiable: 4 contact points enabling stimulation adjustment**
- **Reversible: can be turned off and mechanism removed**

Deep brain stimulation for severe OCD


Target 1:

Anterior Limb Internal Capsule (ALIC); Nuttin et al 1999, 2003

- Targets the same area as anterior capsulotomy
- Affects ventral fibres in ALIC connecting ACC and OFC with thalamus
- Additional connections with amygdala, hippocampus and limbic areas
-



Courtesy of Suzanne Haber




Tyagi et al 2019

Deep brain stimulation for severe OCDC

Target 2:

Anteromedial Subthalamic Nucleus, Mallet et al 2008


Based on observations of 3 patients with STN DBS for Parkinson's disease and co-morbid OCD
Mallet et al 2002; Fontaine et al 2004



Haber et al 2020

amSTN receives input directly from

- ventral anterior cingulate cortex
- medial orbitofrontal cortex
- dorsal anterior cingulate



Mallet et al 2008

Deep brain stimulation for severe OCD

Main Study Outcomes

ALIC1: Greenberg et al 2010, 3 USA centres; 1 Belgium
26 patients YBOCS > 28-30
>35% reduction in YBOCS

ALIC2: Denys et al 2010, 1 centre Holland
Randomised double blind component
Response >35% reduction in YBOCS
YBOCS >28
16 patients

amSTN: Mallet et al 2008, 10 centres in France
Randomised double blind cross over design
16 patients: YBOCS >25
Response >25% reduction in YBOCS

| | STN | ALIC1 | ALIC2 |
|--|-----|-------|-------|
| Mean reduction in YBOCS scores | 8.9 | 12.5 | 15.7 |
| Response rate | 56% | 61.5% | 56% |
| Reduction in YBOCS to mild/subclinical | 25% | 38% | 50% |
| Reduction in depression scores | No | Yes | Yes |


Yale Brown Obsessive Compulsive Scale (YBOCS)

0–7 sub-clinical
8–15 mild
16–23 moderate
24–31 severe
32–40 extreme

Response: 35% reduction YBOCS

Deep brain stimulation for severe OCD

Main Outcomes: OCD, Mood and Cognitive Flexibility



amSTN v ALIC DBS: 6 patients, 4 electrodes

- OCD: YBOCS significantly reduced by amSTN and VC/VS DBS; no statistical difference
- Mood: MADRS significantly reduced by amSTN and VC/VS DBS; VC/VS statistically greater than amSTN DBS
- Cognitive flexibility: significantly improved by amSTN; not by VC/VS DBS

MRI Connectomics to define targets

Post-op 1.5 MRIT images of electrode placement and identification of active contacts


Volumes of tissue activation calculated from active contacts and optimum stimulation amplitudes

ALIC electrodes

- Dorsal contacts effective
- VAS confined to ventral anterior internal capsule
- Mean stimulation = 5.85V


amSTN electrodes

- Ventral contacts effective
- VAS centred on the anterior, inferior medial STN
- Mean stimulation = 1.56V



Preop diffusion weighted 3T MRI: ventral capsule tractography from volumes of tissue activation


Average group tractography from VC-VTA



ALIC VTAs connected to:

- medial orbitofrontal cortex
- mediodorsal thalamus
- amygdalofugal pathway
- habenulo-interpeduncular tract

Preop diffusion weighted 3T MRI: subthalamic nucleus tractography from volumes of tissue activation




amSTN VTAs connected to:


- lateral orbitofrontal cortex
- dorsal anterior cingulate cortex
- dorsolateral prefrontal cortex
- medial forebrain bundle

How do DBS findings fit with neurobiology of OCD?

Milad and Rauch 2012



Krack et al., 2010




Abnormal cortico-striatal-thalamic-cortical loops
 Cortical and striatal areas are hypermetabolic
 DBS thought to inhibit activity in OCD circuitry
 DBS of ventral ALIC likely to dampen ACC/OFC loops

amSTN receives direct input from ACC, OFC and DLPFC
 'Limbic hyperdirect pathway'
 Enables inhibition of programming in basal ganglia
 STN DBS allows interruption of compulsions and obsessions
 By improving cognitive flexibility

A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder.

Li et al. 2020 Nat Commun

Is there a common pathway affected by DBS of ALIC and STN DBS related to clinical outcome?




Volumes of tissue activation calculated from active contacts and optimum stimulation amplitudes

Tractography from VTAs for each cohort

Used difference in YBOCS pre and post DBS
To 'weight' each fibre


ALIC (Cologne)

STN (Grenoble)




All connected fibres

Fibres predicting +ve YBOCS outcome



Li et al 2020



Fibre bundle associated with clinical improvement from either STN and ALIC sites. Madrid and London cohorts overlapped with this pathway

Identified Tract predicting positive outcome:

Connects STN and mediodorsal nucleus of thalamus, traverses through ALIC to dorsal anterior cingulate cortex and ventrolateral prefrontal cortex

Deep Brain Stimulation for Severe Treatment Resistant Depression


Mayberg et al., 2005, Neuron

Deep Brain Stimulation for Treatment-Resistant Depression


Cingulate Area 25

N=6

'All patients spontaneously reported acute effects including "sudden calmness or lightness," "disappearance of the void," sense of heightened awareness, increased interest, "connectedness," and sudden brightening of the room, including a description of the sharpening of visual details and intensification of colors'




Deep Brain Stimulation for Severe Treatment Resistant Depression



Mayberg et al. 1999

Cg25 – hyperactive in depression; normalised with treatments



Crowell et al 2019 American Journal of Psychiatry

Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression

The BROADEN Study 2012-2017, Holtzheimer et al Lancet Psychiatry 2017

Brodman's Area 25 DBS, 15 centres

Staggered start for 6 months in 1/3

Interim analysis when 90 reached 6 months


Needed 40% to reduce depression scores by 40%

20% reached outcome criterion, 5% in remission with active DBS


17% and 7% in remission with inactive DBS

Trial halted.

24 month follow-up: 77





| Number at risk | Baseline | 3 months | 6 months | 9 months | 12 months |
|-------------------|----------|----------|----------|----------|-----------|
| Stimulation group | 60 | 60 | 56 | 53 | 53 |
| Control group | 30 | 30 | 29 | 29 | 27 |




Dougherty et al 2015, Biological Psychiatry

A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule for Chronic Treatment-Resistant Depression



MADRS Percent Change, Blinded Phase, by Group





20% responded following the trial



Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial

10/25 responders

Design: patients were optimised before DBS withdrawal



A systematic review and meta-analysis of deep brain stimulation for depression




190 patients: depression scores and response rate favours DBS

1 case report

10 stereoelectroencephalography electrodes (160 contacts) implanted in:

- orbitofrontal cortex (OFC)
- amygdala, hippocampus,
- ventral capsule/ventral striatum (VC/VS)
- subgenual cingulate (SGC)

stimulation at different sites alleviated anxiety, boosting energy levels, restoring pleasure in everyday activities depended on the mental state at the time



Summary

DBS has been in use as a clinical procedure for severe Parkinson's disease for several decades

Despite successful application for severe OCD and depression this remains a research procedure in UK

In USA OCD DBS has FDA exemption on compassionate grounds but insurance companies are not obliged to fund it

In USA DBS for depression remains a research procedure

Future work will refine network targets using procedures such as connectomics to improve outcomes